IN8bio gains after new preclinical data for nsCAR-T cell therapy platform

seekingalpha04-10

Shares of IN8bio (NASDAQ:INAB) rose about 5% on Wednesday, after the company reported new preclinical data that supports the potential for the proprietary nsCAR platform to selectively eliminate ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426824497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-10 21:49","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2426824497","market":"sh","top_or_hot":-1,"title":"IN8bio gains after new preclinical data for nsCAR-T cell therapy platform","media":"seekingalpha","content":"<div>\n<p>Shares of IN8bio (NASDAQ:INAB) rose about 5% on Wednesday, after the company reported new preclinical data that supports the potential for the proprietary nsCAR platform to selectively eliminate ...</p>\n\n<a href=\"https://seekingalpha.com/news/4088594-in8bio-gains-after-new-preclinical-data-for-nscar-t-cell-therapy-platform\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IN8bio gains after new preclinical data for nsCAR-T cell therapy platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIN8bio gains after new preclinical data for nsCAR-T cell therapy platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-10 21:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4088594-in8bio-gains-after-new-preclinical-data-for-nscar-t-cell-therapy-platform><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of IN8bio (NASDAQ:INAB) rose about 5% on Wednesday, after the company reported new preclinical data that supports the potential for the proprietary nsCAR platform to selectively eliminate ...</p>\n\n<a href=\"https://seekingalpha.com/news/4088594-in8bio-gains-after-new-preclinical-data-for-nscar-t-cell-therapy-platform\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://seekingalpha.com/news/4088594-in8bio-gains-after-new-preclinical-data-for-nscar-t-cell-therapy-platform","article_id":"2426824497","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426824497","pubTimestamp":1712756954,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of IN8bio  rose about 5% on Wednesday, after the company reported new preclinical data that supports the potential for the proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue. The data supports the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target, the company said.  The data was presented in a poster session at the American Association for Cancer Research Annual Meeting 2024 on April 9, 2024. IN8bio's nsCAR platform is based on the natural ability of gamma-delta T cells to distinguish between healthy and malignant tissue. “We are now conducting further optimization to improve the integration of membrane-bound IL-15 co-expression to potentially enhance both the efficacy and safety of next-generation adoptive cell therapies against a wider spectrum of cancers,” said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","INAB":"IN8bio, Inc.","BK4139":"生物科技"},"translate_title":"nsCAR-T细胞治疗平台获得新的临床前数据后，IN8bio获得收益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INAB":1},"content_text":"Shares of IN8bio (NASDAQ:INAB) rose about 5% on Wednesday, after the company reported new preclinical data that supports the potential for the proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue. The data supports the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target, the company said.  The data was presented in a poster session at the American Association for Cancer Research Annual Meeting 2024 on April 9, 2024. IN8bio's nsCAR platform is based on the natural ability of gamma-delta T cells to distinguish between healthy and malignant tissue. “We are now conducting further optimization to improve the integration of membrane-bound IL-15 co-expression to potentially enhance both the efficacy and safety of next-generation adoptive cell therapies against a wider spectrum of cancers,” said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. INAB +11.00% premarket to $1.21. Source: Press Release    More on IN8bio  Seeking Alpha’s Quant Rating on IN8bio Historical earnings data for IN8bio Financial information for IN8bio","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426824497"}